Compare Abeona Therapeutics Inc (ABEO) vs iShares 3 7 Year Treasury Bond ETF (IEI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abeona Therapeutics Inc vs iShares 3 7 Year Treasury Bond ETF — how do they compare? Abeona Therapeutics Inc trades at $7.51 (market cap $421.19M), while iShares 3 7 Year Treasury Bond ETF trades at $116.46. The key difference: Abeona Therapeutics Inc is trading nearer its 52-week high, iShares 3 7 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| ABEO | IEI | |
|---|---|---|
Market Cap | $421.19M | — |
Sector | Health | Fixed Income |
52-Week High | $7.45 | $120.72 |
52-Week Low | $4.17 | $116.16 |
Enterprise Value | $276.10M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.40, down 0.67% on the day, with a bullish technical signal from moving averages. The company reported strong Q1 2026 results with revenue growth and beat EPS estimates for three consecutive quarters. Recent news includes CMS granting NTAP status for ZEVASKYN and expansion of its treatment center network, indicating positive commercial momentum.
Outlook is supported by analyst consensus (66.7% buy ratings) and robust profitability metrics, but risks include high P/S ratio, negative operating cash flow, and a shareholder investigation. The stock's valuation remains attractive on P/E and EV/EBITDA bases, though execution on revenue growth is critical for sustained upside.
IEI, the iShares 3-7 Year Treasury Bond ETF, trades at $116.46, up 0.18% on the day, amid a bearish technical signal from moving averages and neutral oscillators. The ETF maintains a steady dividend payout schedule, with recent distributions around $0.37 per share. Market sentiment is influenced by rising Treasury yields and inflation concerns, as highlighted in recent financial news.
The outlook for IEI is cautious due to potential Federal Reserve rate hikes and inflation pressures, which could pressure bond prices. Opportunities lie in its government backing and lower volatility, but risks include interest rate sensitivity and macroeconomic shifts affecting yield curves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About iShares 3 7 Year Treasury Bond ETF
IEI tracks the ICE U.S. Treasury 3-7 Year Bond Index, offering exposure to intermediate-term government debt. It serves as a conservative middle ground in the Treasury yield curve, providing higher yields than short-term bills with less volatility than long-term bonds.
Read more on IEI →
